Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07847437
Starting soon Not applicable

Progressive Heat Exposure and Physiological Strain

NCT07847437 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-10-01
Last updated
2026-09-29

Condition(s) studied

Body Temperature ChangesHeat StressHeat ExposureHeat FatigueWork Related StressPhysiological Stress

Investigational drug(s) / intervention(s)

Constant Heat ExposureProgressively Increasing Heat Exposure

Constant Heat Exposure: Participants complete a simulated occupational workday under constant environmental conditions, with WBGT maintained at 28°C throughout the morning and afternoon work periods.

Progressively Increasing Heat Exposure: Participants complete a simulated occupational workday in which WBGT progressively increases from morning to afternoon while maintaining a mean daily WBGT of 28°C.

Study summary

Occupational heat-stress guidelines are commonly based on the level of environmental heat exposure and are largely derived from studies conducted under constant environmental conditions. However, outdoor workers are typically exposed to dynamic conditions, with environmental heat often increasing progressively from morning to afternoon. Consequently, workers may experience substantially different patterns of heat exposure across the workday even when average daily heat exposure is equivalent. It remains unclear whether the temporal pattern of heat exposure influences the amount of work that can be performed or the physiological strain experienced during a workday. Understanding these responses is important for determining whether occupational heat-stress guidelines developed under constant laboratory conditions adequately protect workers exposed to progressively changing environmental conditions.

The primary objective of this study is to determine whether the temporal pattern of heat exposure influences work performed and physiological heat strain during a simulated occupational workday in healthy middle-aged and older men. Participants will complete two 9-hour simulated workdays consisting of a 4-hour morning work period, a 1-hour lunch break, and a 4-hour afternoon work period. During one trial, wet-bulb globe temperature (WBGT) will remain constant at 28°C throughout the workday, whereas during the other trial, WBGT will progressively increase from morning to afternoon to simulate the changing environmental conditions of a typical hot summer workday. Both trials will have the same mean daily WBGT of 28°C. Participants will perform moderate-intensity treadmill exercise, and measures including total work performed, core temperature, heart rate, and time to the initial stay-time threshold will be assessed to determine whether constant and progressively increasing heat exposures produce different physiological and work-performance responses across the workday.

Eligibility

Sex
MALE
Min age
45 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Are male. * Do not smoke or have been smoke free for at least 5 years. * English or French speaking. * Ability to provide informed consent. * Are physically active (engage in exercise at least 2 times per week for ≥30 minutes) Exclusion Criteria: * Are regularly exposed to hot environments (e.g., occupational heat exposure) * Experience claustrophobia or discomfort in enclosed environments * Episode(s) of severe hypoglycemia (requiring the assistance of another person) within the previous year, or inability to sense hypoglycemia (hypoglycemia unawareness). * Serious complications related to diabetes (gastroparesis, renal disease, uncontrolled hypertension, severe autonomic neuropathy). * Uncontrolled hypertension - BP \>150 mmHg systolic or \>95 mmHg diastolic in a sitting position. * Restrictions in physical activity due to disease (e.g. intermittent claudication, renal impairment, active proliferative retinopathy, unstable cardiac or pulmonary disease, disabling stroke, severe arthritis, etc.). * Use of or changes in medication judged by the patient or investigators to make participation in this study inadvisable. * Cardiac abnormalities identified during screening

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Ottawa Ottawa Ontario

More University of Ottawa trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07847437 on ClinicalTrials.gov ↗ ← All trials in Canada